Subtype
Lung Carcinoma
CI-CAN-00001086Explore in graph →
2,130 active trials51 approved drugs598 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001086Explore in graph →
Clinical trials
7,792 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,179)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00097851 | Trial of PI-88 With Docetaxel in Advanced Non-Small-Cell Lung Cancer (NSCLC) | completed | Phase 2 | 100 | Cellxpert Biotechnology Corp.INDUSTRY | 1 | Jun 27, 2022 | clinicaltrials |
| NCT02920476 | TAS-102 in Previously Treated Unresectable or Metastatic Squamous Cell Lung Carcinoma (UF-STO-LUNG-003) | completed | Phase 2 | 4 | University of FloridaOTHER | 1 | Jun 23, 2022 | clinicaltrials |
| NCT02648724 |
| Sym015 (Anti-MET) in Patients With Advanced Solid Tumor Malignancies |
| completed |
| Phase 1 / Phase 2 |
| 57 |
| Symphogen A/SINDUSTRY |
| 6 |
| Jun 22, 2022 |
| clinicaltrials |
| NCT00376623 | Efficacy and Safety of BI 2536 in Advanced or Metastatic Non Small Cell Lung Cancer | completed | Phase 2 | 96 | Boehringer IngelheimINDUSTRY | 1 | Jun 21, 2022 | clinicaltrials |
| NCT02183870 | EUCROSS: European Trial on Crizotinib in ROS1 Translocated Lung Cancer(EUCROSS) | completed | Phase 2 | 34 | University of CologneOTHER | 3 | Jun 16, 2022 | clinicaltrials |
| NCT04636762 | A Study of Concurrent Chemoradiation With Atezolizumab in Participants With Untreated Extensive-Stage (ES) Small Cell Lung Cancer (SCLC) | completed | Phase 2 | 40 | Second Xiangya Hospital of Central South UniversityOTHER | 1 | Jun 14, 2022 | clinicaltrials |
| NCT03717155 | Study of Avelumab and Cetuximab Plus Gemcitabine and Cisplatin in Participants With NSCLC | completed | Phase 2 | 43 | Merck KGaA, Darmstadt, GermanyINDUSTRY | 3 | Jun 6, 2022 | clinicaltrials |
| NCT02684461 | Phase II Trial of Sequential Consolidation With Pembrolizumab Followed by Nab-paclitaxel | completed | Phase 2 | 20 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Jun 3, 2022 | clinicaltrials |
| NCT03365791 | PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies | completed | Phase 2 | 76 | Novartis PharmaceuticalsINDUSTRY | 1 | May 27, 2022 | clinicaltrials |
| NCT03812809 | A Phase IIb Study of BPI-7711 Capsule in Non-small Cell Lung Cancer Patients With T790M Mutation Positive | completed | Phase 2 | 226 | Beta Pharma ShanghaiINDUSTRY | 1 | May 19, 2022 | clinicaltrials |
| NCT00887783 | Navelbine And Radiotherapy in Locally Advanced Lung Cancer(NARLAL) | completed | Phase 2 | 117 | Odense University HospitalOTHER | 1 | May 17, 2022 | clinicaltrials |
| NCT03386955 | BPI-7711 Capsule in Patients With EGFR Mutation T790M Positive Non-small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 215 | Beta Pharma ShanghaiINDUSTRY | 1 | May 16, 2022 | clinicaltrials |
| NCT00364780 | Study of XL647 in Subjects With Non-Small-Cell Lung Cancer | completed | Phase 2 | 55 | Kadmon Corporation, LLCINDUSTRY | 1 | May 13, 2022 | clinicaltrials |
| NCT00522145 | Study of XL647 in Subjects With NSCLC Who Have Progressed After Responding to Treatment With Gefitinib or Erlotinib | completed | Phase 2 | 41 | Kadmon Corporation, LLCINDUSTRY | 1 | May 13, 2022 | clinicaltrials |
| NCT02470468 | Evaluation of Safety and Efficacy of DCVAC/LuCa (Immunotherapy of Lung Cancer) in Patients With Metastatic Lung Cancer | completed | Phase 1 / Phase 2 | 105 | SOTIO a.s.INDUSTRY | 2 | May 4, 2022 | clinicaltrials |
| NCT03268057 | VX15/2503 in Combination With Avelumab in Advanced Non-small Cell Lung Cancer(CLASSICAL-Lung) | completed | Phase 1 / Phase 2 | 62 | Vaccinex Inc.INDUSTRY | 1 | May 2, 2022 | clinicaltrials |
| NCT03562871 | IO102 With Pembrolizumab, With or Without Chemotherapy, as First-line Treatment of Metastatic NSCLC | completed | Phase 1 / Phase 2 | 109 | IO BiotechINDUSTRY | 4 | Apr 21, 2022 | clinicaltrials |
| NCT03633110 | Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine | completed | Phase 1 / Phase 2 | 24 | Genocea Biosciences, Inc.INDUSTRY | 1 | Apr 19, 2022 | clinicaltrials |
| NCT01134250 | Combination Therapy of F16IL2 and Paclitaxel in Solid Tumour Patients | completed | Phase 1 / Phase 2 | 48 | Philogen S.p.A.INDUSTRY | 1 | Apr 15, 2022 | clinicaltrials |
| NCT00152477 | A Study of Paclitaxel/Carboplatin With or Without CDP791 in Patients With Lung Cancer | completed | Phase 2 | 165 | UCB PharmaINDUSTRY | 3 | Apr 12, 2022 | clinicaltrials |
| NCT01003964 | Pharmacogenomic Study for Providing Personalized Strategy to the Treatment of Non-small Cell Lung Cancer (NSCLC) IIIB/IV | completed | Phase 2 | 289 | National Cancer Center, KoreaOTHER_GOV | 1 | Apr 12, 2022 | clinicaltrials |
| NCT02347917 | A Study of BBI608 in Combination With Pemetrexed and Cisplatin in Adult Patients With Malignant Pleural Mesothelioma | completed | Phase 1 / Phase 2 | 28 | Sumitomo Pharma Co., Ltd.INDUSTRY | 1 | Apr 12, 2022 | clinicaltrials |
| NCT01156545 | BIBW 2992 Plus Simvastatin vs. BIBW 2992 in Previously Treated Patients With Advanced Non-adenocarcinomatous NSCLC | completed | Phase 2 | 68 | National Cancer Center, KoreaOTHER_GOV | 1 | Apr 6, 2022 | clinicaltrials |
| NCT02417701 | Sapanisertib in Treating Patients With Stage IV or Recurrent Lung Cancer | completed | Phase 2 | 34 | National Cancer Institute (NCI)NIH | 1 | Apr 5, 2022 | clinicaltrials |
| NCT02616393 | Phase 2 Study of Study of Tesevatinib in Subjects With NSCLC and Brain or Leptomeningeal Metastases | completed | Phase 2 | 36 | Kadmon Corporation, LLCINDUSTRY | 1 | Mar 16, 2022 | clinicaltrials |
| NCT00600015 | Sorafenib/Erlotinib Versus Erlotinib Alone in Previously Treated Advanced Non-Small-Cell Lung Cancer (NSCLC) | completed | Phase 2 | 166 | SCRI Development Innovations, LLCOTHER | 1 | Mar 10, 2022 | clinicaltrials |
| NCT03798743 | Phase II Study on Sintilimab Combined With Docetaxel for Chemotherapy Failure Advanced NSCLC: the SUCCESS Study(SUCCESS) | completed | Phase 2 | 30 | Hunan Province Tumor HospitalOTHER | 1 | Mar 2, 2022 | clinicaltrials |
| NCT04144582 | Sintilimab Combined With Docetaxel for Standard Chemotherapy Failure Non-driver Gene Mutation Metastatic Non-small Cell Lung Cancer | completed | Phase 2 | 30 | Yongchang ZhangOTHER | 1 | Mar 2, 2022 | clinicaltrials |
| NCT03794544 | Neoadjuvant Durvalumab Alone or in Combination With Novel Agents in Resectable Non-Small Cell Lung Cancer | completed | Phase 2 | 84 | MedImmune LLCINDUSTRY | 7 | Feb 24, 2022 | clinicaltrials |
| NCT01935336 | Study of Ponatinib in Patients With Lung Cancer Preselected Using Different Candidate Predictive Biomarkers | completed | Phase 2 | 171 | University of Colorado, DenverOTHER | 1 | Feb 11, 2022 | clinicaltrials |
| NCT00698815 | Pemetrexed and/or Sunitinib as Second-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer | completed | Phase 2 | 130 | National Cancer Institute (NCI)NIH | 1 | Feb 8, 2022 | clinicaltrials |
| NCT02044328 | Icotinib as an Adjuvant Therapy for Patients With Stage IIA-IIIA Adenocarcinoma With EGFR Mutation(ICAPE) | completed | Phase 2 | 79 | Betta Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Feb 8, 2022 | clinicaltrials |
| NCT03647488 | Study of Capmatinib and Spartalizumab Combination Therapy vs Docetaxel in Non-small Cell Lung Cancer | completed | Phase 2 | 18 | Novartis PharmaceuticalsINDUSTRY | 6 | Jan 24, 2022 | clinicaltrials |
| NCT03659578 | Study of Thymosin α1 to Reduce Acute Pneumonia For Bulky None-small Cell Lung Cancer | completed | Phase 2 | 69 | Sun Yat-sen UniversityOTHER | 1 | Jan 3, 2022 | clinicaltrials |
| NCT00741988 | Ixabepilone and Carboplatin +/- Bevacizumab in Advanced Non-Small-Cell Lung Cancer | completed | Phase 2 | 82 | SCRI Development Innovations, LLCOTHER | 1 | Dec 15, 2021 | clinicaltrials |
| NCT02936323 | PEN-221 in Somatostatin Receptor 2 Expressing Advanced Cancers Including Neuroendocrine and Small Cell Lung Cancers | completed | Phase 1 / Phase 2 | 89 | Tarveda TherapeuticsINDUSTRY | 2 | Dec 14, 2021 | clinicaltrials |
| NCT00695292 | Irinotecan, Carboplatin, and Sunitinib in First Line Extensive-Stage Small Cell Lung Cancer | completed | Phase 2 | 37 | SCRI Development Innovations, LLCOTHER | 1 | Nov 22, 2021 | clinicaltrials |
| NCT03371979 | Pegzilarginase and Pembrolizumab for Extensive Disease Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 68 | Aeglea BiotherapeuticsINDUSTRY | 2 | Nov 4, 2021 | clinicaltrials |
| NCT01757288 | Phase I/II NabPaclitaxel, Paclitaxel&Carboplatin w RTX Followed by Consolidation in Patients w Favorable Prognosis Inoperable Stage IIIA/B NSCLC | completed | Phase 1 / Phase 2 | 98 | University of Texas Southwestern Medical CenterOTHER | 1 | Oct 28, 2021 | clinicaltrials |
| NCT01951586 | Denosumab in Combination With Chemotherapy as First-line Treatment of Metastatic Non-small Cell Lung Cancer | completed | Phase 2 | 226 | AmgenINDUSTRY | 10 | Oct 25, 2021 | clinicaltrials |
| NCT03574753 | Lung-MAP S1400K: c-MET Positive | completed | Phase 2 | 28 | SWOG Cancer Research NetworkNETWORK | 1 | Oct 18, 2021 | clinicaltrials |
| NCT01905657 | Study of Two Doses of Pembrolizumab (MK-3475) Versus Docetaxel in Previously Treated Participants With Non-Small Cell Lung Cancer (MK-3475-010/KEYNOTE-010) | completed | Phase 2 / Phase 3 | 1,034 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Oct 6, 2021 | clinicaltrials |
| NCT02303977 | Phase II Study of Abraxane and Gemicitabine in Patients With Advanced Adenocarcinoma Non-Small Cell Lung Cancer Progressing After First-Line Platinum-Based Chemotherapy | completed | Phase 2 | 37 | Abramson Cancer Center at Penn MedicineOTHER | 0 | Sep 29, 2021 | clinicaltrials |
| NCT03261947 | A Study to Evaluate the Safety, Tolerability, and Activity of TAK-931 in Participants With Metastatic Pancreatic Cancer, Metastatic Colorectal Cancer, and Other Advanced Solid Tumors | completed | Phase 2 | 101 | Millennium Pharmaceuticals, Inc.INDUSTRY | 2 | Sep 20, 2021 | clinicaltrials |
| NCT00871923 | Tarceva With Whole Brain Radiation Therapy - Brain Mets From Non-Small Cell Lung Cancer | completed | Phase 2 | 44 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 16, 2021 | clinicaltrials |
| NCT01449461 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumor Activity of the Oral Anaplastic Lymphoma Kinase (ALK)/Epidermal Growth Factor Receptor (EGFR) Inhibitor Brigatinib (AP26113) | completed | Phase 1 / Phase 2 | 137 | Ariad PharmaceuticalsINDUSTRY | 0 | Aug 17, 2021 | clinicaltrials |
| NCT02450539 | A Study of Abemaciclib (LY2835219) in Participants With Stage IV Squamous Non-small Cell Lung Cancer | completed | Phase 2 | 159 | Eli Lilly and CompanyINDUSTRY | 13 | Aug 13, 2021 | clinicaltrials |
| NCT01631552 | Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer | completed | Phase 1 / Phase 2 | 515 | Gilead SciencesINDUSTRY | 1 | Aug 12, 2021 | clinicaltrials |
| NCT02674568 | Study of Rovalpituzumab Tesirine (SC16LD6.5) for Third-Line and Later Treatment of Subjects With Relapsed or Refractory Delta-Like Protein 3-Expressing Small Cell Lung Cancer(TRINITY) | completed | Phase 2 | 342 | AbbVieINDUSTRY | 0 | Jul 30, 2021 | clinicaltrials |
Data updated 23 days agoSource updated Jun 27, 2022source: clinicaltrials